Does Medicare Cover Prostate Cancer Screening? (2026)

Quick Answer: What Medicare Pays for Prostate Cancer Screening in 2026

Yes. Medicare Part B covers an annual prostate cancer screening for men age 50 and older: the PSA blood test is covered at no cost, while the digital rectal exam (DRE) is subject to the 2026 Part B deductible ($283) and 20% coinsurance. Medicare Advantage plans must offer the same PSA benefit at $0. Diagnostic follow-up such as a biopsy or MRI after an abnormal result is billed as standard care, not free screening.

What Original Medicare Covers: PSA Test vs. Digital Rectal Exam

Original Medicare treats the two components of prostate cancer screening differently. The PSA blood test is authorized under Section 1861(oo) of the Social Security Act as a standalone preventive benefit, so Medicare pays 100% of the approved amount once every 12 months for men age 50 and older, with $0 out-of-pocket cost. The digital rectal exam, by contrast, is typically performed and billed together with the office visit at which it occurs, so it falls under standard Part B outpatient rules rather than the $0 preventive carve-out.

For 2026, that means the DRE (and the associated office visit) is subject to the annual Part B deductible of $283, then 20% coinsurance on the Medicare-approved amount once the deductible is met. Medicare Part A does not typically apply to routine screening, since it covers inpatient hospital stays; Part A only becomes relevant if a rare complication from a biopsy requires hospital admission, in which case the 2026 Part A inpatient deductible of $1,736 applies per benefit period.

What Medicare Advantage May Add in 2026

Medicare Advantage plans are required by federal law to cover every preventive service Original Medicare covers at the same $0 cost, including the annual PSA test. Where plans differ is on the digital rectal exam and diagnostic follow-up: some Medicare Advantage plans bundle office visit copays that make a DRE-inclusive visit cheaper than Original Medicare's deductible-plus-coinsurance structure, while HMO-style Medicare Advantage plans require the ordering provider and any lab to be in-network or the claim can be denied entirely.

Check your plan's Evidence of Coverage document for the exact office visit copay that applies when a DRE is performed, and confirm whether a urology referral requires prior authorization before a biopsy or prostate MRI is ordered, since Medicare Advantage plans can require prior authorization for diagnostic imaging and procedures in ways Original Medicare does not.

Eligibility and Risk-Based Screening: Age 50, No Cap, and High-Risk Groups

Medicare's statutory screening benefit covers any male beneficiary enrolled in Part B who is age 50 or older, with no upper age limit and no requirement for symptoms or family history. That statutory floor is broader than the U.S. Preventive Services Task Force guidance, which gives PSA screening a Grade C recommendation focused on shared decision-making for men ages 55 to 69 and generally advises against routine screening for men 70 and older because of the risk of false positives leading to unnecessary biopsies.

African American men and men with a first-degree relative diagnosed with prostate cancer face roughly double the lifetime risk of the disease, and many urology groups recommend these men start conversations about screening as early as age 40 to 45. Medicare, however, does not lower its statutory age threshold for high-risk groups; the benefit begins at 50 regardless of risk factors, so higher-risk men under 65 who are not yet Medicare-eligible should discuss earlier screening options with their doctor under whatever coverage they carry before Medicare eligibility begins.

Cost of Diagnostic Follow-Up After an Abnormal Result (2026)

An elevated PSA reading or a suspicious digital rectal exam finding triggers a shift from preventive screening to diagnostic workup, and Medicare's cost rules shift with it. A repeat diagnostic PSA, a urology consultation, an MRI of the prostate, and a needle biopsy are all billed under standard Part B rules: the 2026 Part B deductible of $283 applies first if not already met for the year, then 20% coinsurance on the Medicare-approved amount for each service.

For beneficiaries without Medicare or a supplement, FAIR Health consumer cost data shows a prostate MRI typically runs $1,200 to $3,000 out-of-pocket in 2026 depending on region and facility, and a transrectal or transperineal needle biopsy typically runs $1,000 to $3,500 including pathology review. Medicare-approved amounts for the same services are substantially lower than commercial self-pay rates, which is one reason staying enrolled in Part B matters even when a screening result triggers diagnostic care rather than a free preventive test.

If a biopsy confirms a prostate cancer diagnosis, the treatment path shifts to a different set of Medicare rules entirely. Surgery and radiation are billed under Part A or Part B depending on setting, while oral hormone therapy or oral chemotherapy drugs prescribed after diagnosis are typically covered under Medicare Part D, subject to that plan's formulary tier and the 2026 Part D out-of-pocket cap of $2,100.

Standalone Supplemental Options: What Medigap Covers

Medigap (Medicare Supplement) policies exist specifically to cover the cost-sharing gaps Original Medicare leaves behind, and prostate cancer screening follow-up is a textbook example. Medigap Plan G, one of the most popular plan letters, covers the Part B 20% coinsurance in full and covers the Part B deductible for beneficiaries who purchased their policy before 2020 (newer Plan G enrollees pay the 2026 deductible of $283 once, then owe $0 for the rest of the year). Plan N covers the coinsurance but may carry small copays for office visits.

Medigap cannot be combined with Medicare Advantage: a beneficiary chooses one path or the other. Men enrolled in Original Medicare who anticipate needing a biopsy or repeat imaging after an abnormal PSA result, particularly those with a family history of prostate cancer, often find that a Medigap policy pays for itself the first year a diagnostic workup is needed, since a single biopsy's 20% coinsurance alone can exceed $200 to $700 depending on the facility.

Coverage Before Medicare: ACA-Compliant Marketplace Plans and Prostate Screening

Men under 65 who are not yet Medicare-eligible rely on employer coverage or ACA-compliant marketplace plans, and the rules there differ from Medicare's. Because PSA screening carries a USPSTF Grade C recommendation rather than Grade A or B, ACA-compliant plans are not federally required to waive cost-sharing for it the way they must for Grade A and B essential health benefits like colorectal cancer screening; many insurers cover it anyway, but check your plan's preventive services list before assuming it is free.

One protection carries over regardless of age: since the ACA took effect, an ACA-compliant plan cannot deny coverage, charge higher premiums, or exclude benefits because of a preexisting condition such as an elevated PSA history or a prior prostate biopsy. That protection did not exist before 2014, when men with a documented history of prostate concerns could face denial or exclusion riders on individual market plans.

Does Original Medicare cover prostate cancer screening?

Yes. Original Medicare Part B covers an annual PSA blood test at $0 for men age 50 and older, with no deductible or copay. The digital rectal exam performed at the same visit is subject to the 2026 Part B deductible ($283) and 20% coinsurance because it is billed with the office visit rather than as a standalone preventive service.

Does Medicare Advantage cover prostate cancer screening?

Yes. Every Medicare Advantage plan is required to cover the annual PSA test at $0, matching Original Medicare's preventive benefit. Cost-sharing for the digital rectal exam and any office visit copay varies by plan, so check your Evidence of Coverage document. HMO plans typically require in-network providers and labs.

What does a prostate biopsy cost in 2026 if Medicare only covers it partially?

A prostate biopsy is billed as diagnostic care once results move past preventive screening, so the 2026 Part B deductible of $283 applies first, then 20% coinsurance on the Medicare-approved amount. Without Medicare or a supplement, FAIR Health data shows self-pay biopsy costs typically run $1,000 to $3,500 including pathology review.

Does Medigap cover the cost of prostate cancer screening follow-up?

Yes. Medigap plans such as Plan G and Plan N cover the 20% coinsurance that applies to a diagnostic DRE, MRI, or biopsy under Original Medicare, and most plan letters also cover the Part B deductible. Medigap cannot be combined with Medicare Advantage, so beneficiaries must choose one path.

Is prostate cancer screening covered earlier for African American men or men with a family history?

Medicare's statutory benefit still begins at age 50 for all men regardless of risk factors, even though African American men and men with a first-degree relative who had prostate cancer face roughly double the average lifetime risk. Higher-risk men under 65 should discuss earlier screening with their doctor under whatever coverage they carry before Medicare eligibility starts at 65.

When does Medicare treat a PSA test or DRE as diagnostic instead of preventive?

Medicare treats the test as diagnostic whenever it is ordered because of symptoms, an abnormal prior result, or a follow-up to monitor a known condition rather than routine annual screening. Diagnostic tests are billed under standard Part B rules with the deductible and 20% coinsurance, unlike the $0 annual preventive PSA.

What is the difference between the PSA test and the digital rectal exam?

The PSA test is a blood draw that measures prostate-specific antigen, a protein that can be elevated in prostate cancer, benign prostatic hyperplasia, or prostatitis. The digital rectal exam is a physical exam where a doctor checks the prostate for texture or size abnormalities. Medicare covers both once every 12 months but applies different cost-sharing rules to each.

What happens after an abnormal PSA test or DRE result under Medicare?

An abnormal result typically leads to a urology referral, a repeat PSA test, an MRI of the prostate, or a needle biopsy. All of these are billed as diagnostic services under standard Part B rules with the 2026 deductible and 20% coinsurance, not as free preventive screening, so ask your provider to estimate costs before scheduling follow-up care.